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Abstract
In recent years, highly detailed characterization of adult bone marrow (BM) myeloid progeni-
tors has been achieved and, as a result, the impact of somatic defects on different hemato-
poietic lineage fate decisions can be precisely determined. Fetal liver (FL) hematopoietic
progenitor cells (HPCs) are poorly characterized in comparison, potentially hindering the
study of the impact of genetic alterations on midgestation hematopoiesis. Numerous disor-
ders, for example infant acute leukemias, have in utero origins and their study would there-
fore benefit from the ability to isolate highly purified progenitor subsets. We previously
demonstrated that a Runx1 distal promoter (P1)-GFP::proximal promoter (P2)-hCD4 dual-
reporter mouse (Mus musculus) model can be used to identify adult BM progenitor subsets
with distinct lineage preferences. In this study, we undertook the characterization of the
expression of Runx1-P1-GFP and P2-hCD4 in FL. Expression of P2-hCD4 in the FL immu-
nophenotypic Megakaryocyte-Erythroid Progenitor (MEP) and Common Myeloid Progenitor
(CMP) compartments corresponded to increased granulocytic/monocytic/megakaryocytic
and decreased erythroid specification. Moreover, Runx1-P2-hCD4 expression correlated
with several endogenous cell surface markers’ expression, including CD31 and CD45, pro-
viding a new strategy for prospective identification of highly purified fetal myeloid progenitors
in transgenic mouse models. We utilized this methodology to compare the impact of the
deletion of either total RUNX1 or RUNX1C alone and to determine the fetal HPCs lineages
most substantially affected. This new prospective identification of FL progenitors therefore
raises the prospect of identifying the underlying gene networks responsible with greater pre-
cision than previously possible.
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Author summary
The production of red blood cells, platelet-producing megakaryocytes, and immune
response-directing granulocytes and monocytes is initiated at an early stage in the devel-
oping embryo and continues throughout life. The proportion of each cell type varies
depending on the specific needs of the organism. We know that in the mouse embryo,
specialized blood progenitor cells emerge in the fetal liver and produce mature blood cells
in response to different cues. However, it is difficult to distinguish between red blood cell
and white blood cell-producing progenitors with sufficiently high accuracy to study these
cues. For example, we know that several childhood blood disorders, such as leukemias, are
caused by genetic mutations in blood progenitor cells before birth, but studying the effects
of these mutations in a mouse disease model is hampered if we don’t know which blood
progenitor cells to collect. We have used different genetic markers to help distinguish red
blood cell, megakaryocyte and granulocyte/monocyte-producing progenitor cells with a
greater precision than was previously possible. Furthermore, to illustrate how this tech-
nique can be used to study blood disorders, we demonstrated that mutations affecting the
transcription factor Runx1 impair the abilities of different progenitors to produce mature
blood cells in different ways.
Introduction
Definitive hematopoiesis is a complex, multistep process involving increasingly restrictive cell
fate decisions by self-renewing, multipotent hematopoietic stem cells (HSCs). Commitment to
lymphoid, granulocytic/monocytic (GM), megakaryocytic and erythroid lineages occurs
through the differentiation of immature progenitors, and is subject to spatial and temporal con-
trol by intrinsic and extrinsic factors [1,2]. In recent years, high-resolution characterization of
BM progenitor populations has been achieved and this critical advance has allowed detailed
interrogation of the gene regulatory networks which govern normal homeostatic and malignant
hematopoietic differentiation, both in clinical patient samples and adult transgenic mouse mod-
els [3–16]. In particular, various assumptions about the process of myeloid progenitor differenti-
ation have been challenged. For example, the existence of an obligatory intermediate CMP
population, as an ancestor of all committed granulocytic/monocytic, megakaryocytic and ery-
throid progenitors, is now questioned [3,7]. Pronk et al proposed the separation of bone marrow
CMPs into PreGM and PreMegakaryocytic/Erythroid (PreMegE) progenitors, based on CD150/
Endoglin expression [5]. Utilizing a Runx1 dual-reporter mouse model (P1-GFP::P2-hCD4) [17]
(which reflects the alternate use of the two Runx1 promoters) we recently reported that in fact
the P2-hCD4- PreMegE fraction comprises pro-erythroid progenitors, whereas P2-hCD4+ Pre-
MegEs are skewed in favor of megakaryocytic output [18].
Examinations of the roles of developmental transcription factors (TFs), particularly Runx
factors, in the developing mouse embryo have greatly advanced our understanding of the ori-
gins of blood development in utero [19,20]. Runx1 expression is observed in the different
hematopoietic waves: in the earliest primitive myeloid and erythroid progenitors at embryonic
day (E) 7.5, in the intermediate erythromyeloid progenitors (EMPs)/lymphoid progenitors at
E8.5, and in the long-term repopulating HSCs from E10.5 [21–27]. Indeed, HSC emergence
through endothelial-to-hematopoietic transition (EHT) is directed by P2-expressed RUNX1B
[17,28].
The fetal liver is seeded initially by EMPs, followed by definitive HSCs from E11.5, and
forms an ideal niche for hematopoietic stem and progenitor cell (HSPC) expansion and
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maturation [21,29,30]. By E14.5, a definitive hematopoietic stem and progenitor cell hierarchy
is believed to be firmly established in the fetal liver [31,32]. Equivalents of previously described
BM HPCs, including MEPs, CMPs, Granulocyte/Monocyte Progenitors (GMPs) and Mega-
karyocyte Progenitors (MkPs), have been identified in E14.5 fetal liver [31,33]. However, the
resolution at which these fetal liver hematopoietic progenitor cells can be identified and iso-
lated is far lower than for their bone marrow equivalents [9,31,34–37]. This hinders the inter-
rogation of this fetal liver hierarchy, particularly in mouse models of hematopoietic disorders
with in utero origins. Indeed, higher-resolution purification of myeloid hematopoietic pro-
genitor cells would allow the execution of transcriptomic and clonogenic lineage analysis to
investigate the disruption of specific gene regulatory networks and the resultant impact on
hematopoietic output. We therefore endeavored to improve our resolution of the specification
of fetal liver myeloid hematopoietic progenitor cells.
Having initially determined that multilineage cultured colony-forming unit (CFU-C) activ-
ity is restricted to the CD55+ CD150+ Megakaryocyte-Erythroid Progenitor (MEP) and Com-
mon Myeloid Progenitor (CMP) compartments, we utilized the Runx1-P1-GFP::P2-hCD4
mouse model to further subdivide these populations. Within the MEP, the P2-hCD4+ fraction
possessed the entirety of its bipotential megakaryocytic/erythroid (Mk/Ery) output. The
P2-hCD4+ CMP, meanwhile, had more balanced myeloid output, in particular decreased ery-
throid specification, than its P2-hCD4- counterpart.
Subsequently, we identified CD31, CD45 and CD48 as candidate markers whose expression
correlated with P2-hCD4. To demonstrate the potential applications of this approach, we char-
acterized perturbations in CD150+ CD31-/+ MEPs and CD150+ CD31low/high CMPs from
Runx1-null (Runx1-flox::Vav1-Cre, Runx1-del[38]) and Runx1c-null (Runx1-P1-MRIPV [39])
mice. Using this approach we revealed fundamental differences between the two mouse mod-
els. Whereas, Runx1-del/del CD31low CMPs have impaired erythroid specification and matura-
tion, Runx1-P1-MRIPV/MRIPV CD31high CMPs have impaired megakaryocytic specification
but normal megakaryocyte and erythroid maturation. This indicates that the RUNX1B and
RUNX1C isoforms fulfill different roles during fetal liver hematopoiesis. Furthermore, it dem-
onstrates the benefits of high specificity fetal liver hematopoietic progenitor isolation for eluci-
dating complex myeloid lineage fate decisions.
Results
Delineating CD150/CD55 expression allows enhanced purification of
immunophenotypic MEP and CMP fractions in E14.5 fetal liver
The existence of a bipotent MEP has long been posited in mid-gestation fetal liver, in addition
to adult bone marrow [3,31]. The multipotent CMP is more controversial, however, with vari-
ous groups reporting that it is actually a heterogeneous population of megakaryocytic/ery-
throid/granulocytic/monocytic progenitors, capable of varying lineage output [5,40]. More
recently, CD150 and CD55 expression have been associated with Mk/Ery potential in adult
hematopoietic progenitors [41]. Therefore, we analyzed CD55/CD150 expression in the E14.5
fetal liver MEP (Lin- SCA1- C-KIT+ (LK) CD16/32low CD34-) and CMP (LK CD16/32low
CD34+) progenitor fractions (Fig 1A and 1B). Additionally, to remove the previously identified
CD41+ MkP fraction [33,42], we analyzed solely CD41- MEPs and CMPs.
In both the CD41- MEP and CMP fractions, three populations were discernible: CD55-
CD150- (4% of MEPs, 52% CMPs); CD55+ CD150- (69% MEPs, 12% CMPs); and CD55+
CD150+ (26% MEPs, 30% CMPs). By contrast, we observed the GMP and MkP populations
were more homogeneous with respect to both CFU-C activity (S1A Fig) and CD150/CD55
expression: 95% of MkPs were CD55+ CD150+ and 91% of GMPs were CD55low CD150low
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(S1B–S1F Fig). We also confirmed that negligible (<1%) CFU-C activity resided in the
remaining cKit- fetal liver fraction (S1A Fig). We therefore proceeded to characterize the dif-
ferentiation potentials of the various CD55/CD150 MEP and CMP subfractions.
Interestingly, CD55- CD150- MEPs did not possess any CFU-C activity in semi-solid mye-
loid MethoCult medium (Fig 1C). Additionally, they did not yield cells expressing either the
erythroid marker TER119, the megakaryocytic marker CD41, the granulocytic/monocytic
markers CD11b/GR1 or the mast/progenitor cell-associated C-KIT following OP9 co-culture
in pro-myeloid medium (Fig 1F and 1G, S1G and S1H Fig). By contrast, CD55- CD150- CMPs
yielded CFU-Cs at 20% plating efficiency, which solely comprised granulocytic (CFU-G),
monocytic/macrophage (CFU-M) and GM (CFU-GM) colonies (Fig 1C and 1E). Additionally,
98% of OP9 co-cultured CD55- CD150- CMP-derived cells were CD11b+ GR1+ granulocytes/
monocytes (Fig 1H and 1I), with just 0.01% being TER119+ erythrocytes and 0.11% CD41+
megakaryocytes.
CD55+ CD150- cells had increased CFU-C activity by comparison (25% for MEPs, 40% for
CMPs, Fig 1C). CD55+ CD150- MEPs solely comprised erythroid colony-forming units
(CFUe, Fig 1D) and produced 92% TER119+ erythroid cells on OP9 (Fig 1F and 1G). CD55+
CD150- CMPs chiefly yielded CFU-G, M and GM colonies, but also comprised a small number
(approximately 1%) of erythroid burst-forming units (BFUe), bipotent megakaryocytic/ery-
throid colony-forming units (CFU-MkE) and multipotential granulocytic/erythroid/mono-
cytic/megakaryocytic colony-forming units (CFU-GEMM, Fig 1E). Accordingly 93% CD11b+
GR1+ granulocytic/monocytic and 1.8% CD41+ megakaryocytic cells resulted from OP9 co-
culture (Fig 1H ang 1I).
Finally, CFU-C activity was chiefly observed in the CD55+ CD150+ fractions (50% for MEPs,
70% for CMPs, Fig 1C). Crucially, the CD55+ CD150+ subpopulation was the only MEP fraction
to demonstrate megakaryocytic/erythroid bipotentiality (yielding 1.2% CFU-Mks and 0.5%
CFU-MkEs, Fig 1D; 79% TER119+ erythrocytes and 14% CD41+ megakaryocytes, Fig 1F and 1G).
Additionally, the CD55+ CD150+ CMP fraction had the broadest range of CFU-C activity, yielding
approximately equal numbers of CFU-M, GM, Mk, MkE, GEMM and BFUe colonies (Fig 1E)
and all three Mk/Ery/GM cell fractions in OP9 co-culture (Fig 1H and 1I). We therefore demon-
strated that inclusion of anti-CD150 and, to a lesser extent, anti-CD55 antibodies in MEP/CMP
isolation protocols aids the purification of highly clonogenic multipotent myeloid progenitors.
The FL Lin- cKithigh Sca1high (LSK) is a highly clonogenic fraction, which can be separated
into long-term repopulating HSC and short-term repopulating Multipotent Progenitor (MPP)
fractions on the basis of CD48 and CD150 expression [32,43] (S1I and S1J Fig). To determine
whether fetal liver LSK hematopoietic stem and progenitor cells are the likely ancestors of the
fetal liver CMPs, MEPs, GMPs and MkPs, we cultured E14.5 fetal liver HSCs and LSK CD48-/+
MPPs in pro-myeloid medium for 20 hours (S1K and S1L Fig). The majority of cultured HSCs
Fig 1. Delineating CD150/CD55 expression allows enhanced purification of immunophenotypic MEP and CMP fractions in
E14.5 fetal liver. A-B. Expression of CD150 and CD55 in wild type (WT) E14.5 fetal liver immunophenotypic MEP and CMP fractions.
A. Representative FACS plots of Lin- Sca1- cKit+ (LK) hematopoietic progenitors (1st panel); LK hematopoietic progenitors: CD16/
32low CD34- MEPs, CD16/32low CD34+ CMPs and CD16/32high CD34+ GMPs (2nd panel); CD41- MEPs (3rd panel); CD150/CD55
expression in MEPs (4th panel); CD41- CMPs (5th panel);; and CD150/CD55 expression in CMPs (6th panel). B. Quantitation of the
proportion of CD55- CD150-, CD55+ CD150- and CD55+ CD150+ MEPs (left) and CMPs (right) as a percentage of total live red blood
cell lysed fetal liver cells. N = 3 C-E. CFU-C activity of CD55- CD150-, CD55+ CD150- and CD55+ CD150+ MEPs and CMPs. C. Total
CFU-C numbers per 100 plated cells. D. Differential (CFUe, BFUe, CFU-Mk and CFU-MkE) activity of MEPs. E. Differential (CFU-G,
CFU-M, CFU-GM, BFUe, CFU-Mk, CFU-MkE and CFU-GEMM) activity of CMPs. N = 3 F-I. Lineage output of OP9 co-cultured MEPs
and CMPs. F. Representative FACS plots of TER119 and CD41 expression of day 7 OP9 co-cultured MEPs. G. Proportion of
TER119+ erythroid cells and CD41+ megakaryocyte cells in day 7 OP9 MEP co-cultures. H. Representative FACS plots of CD11b,
GR1, TER119 and CD41 expression of day 7 OP9 co-cultured CMPs. I. Proportion of CD11b+ GR1+ granulocyte/monocyte cells,
TER119+ erythroid cells and CD41+ megakaryocyte cells in day 7 OP9 CMPs co-cultures. N = 3.
https://doi.org/10.1371/journal.pgen.1007127.g001
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(60%) retained an LSK immunophenotype, but had upregulated CD48. Only 6% of cultured
HSCs had an LK immunophenotype, but within this fraction CD150+/- CMP, CD150+/- MEP,
GMP and MkP fractions were discernible. More convincingly, a large fraction (27%) of cul-
tured LSK CD48+ CD150+ MPPs had acquired an LK immunophenotype, yielding mostly
CD150+ MEPs and MkPs. By contrast, 12% of cultured LSK CD48+ CD150- MPPs had an
MkP, GMP, CD150- MEP or CD150- CMP immunophenotype. This therefore suggests that
fetal liver HSCs are capable of establishing a myeloid progenitor hierarchy, as their LSK
CD48+ MPP progeny give rise to the Sca1- cKit+ MkP, GMP, MEP and CMP progenitors.
The observation that fetal liver HSCs are capable of establishing a hematopoietic stem and
progenitor cell hierarchy does not preclude the possibility that yolk sac erythro-myeloid pro-
genitors (EMPs) could also contribute to these cell populations. To determine whether EMPs
could directly give rise to a hematopoietic progenitor cell profile comparable to that observed
in the fetal liver, we isolated yolk sac cells from E9.5 embryos and cultured them in pro-mye-
loid medium for up to 24 hours (with or without prior explant culture (S1M and S1N Fig)).
We observed that a small proportion of cells (up to 15% in the explant cultures) had the LK
immunophenotype. The majority of these cells were either immunophenotypic GMPs or were
LK CD16/32- CD150- CD41+. No CD150+ LK progenitors were produced in these cultures.
This therefore suggests that yolk sac EMPs are incapable of directly establishing our observed
FL myeloid hematopoietic progenitor hierarchy.
Runx1-P2 reporter expression demarcates mono and bipotent subsets
in the CD150+ MEP
We previously used Runx1-P1-GFP::P2-hCD4 dual-reporter mice to demonstrate that
Runx1-P2 expression coincides with enhanced megakaryocytic specification in adult bone
marrow PreMegEs [18]. Having established that CD150 expression enhances megakaryocyte/
erythroid progenitor isolation in fetal liver MEPs, we tried to improve this further by charac-
terizing Runx1-P1-GFP/P2-hCD4-expressing MEPs (Fig 2A and 2B). In E12.5, E13.5 and E14.5
fetal liver, the CD41- CD150+ MEP fractions were dominated by P1-GFP+ P2-hCD4- cells
(66%, 72% and 80% respectively). P1-GFP- P2-hCD4- populations were also present (25%, 25%
and 13% respectively). However, P1-GFP+ P2-hCD4+ populations were considerably smaller,
at 8%, 3% and 7% of CD41- CD150+ MEPs respectively. Importantly, at each timepoint this
restricted P2-hCD4+ fraction possessed the vast majority of BFUe, CFU-Mk and CFU-MkE
activity (Fig 2C, S2A and S2B Fig). This was particularly marked at E14.5, with this population
yielding 20% CD41+ megakaryocytes following OP9 co-culture, compared to<5% in E12.5
and E13.5 cultures (Fig 2D and 2E, S2C–S2F Fig).
To achieve a more accurate estimate of the potentiality of P2-hCD4- and P2-hCD4+ CD41-
CD150+ MEPs, we performed single cell OP9 co-culture assays (Fig 2F). Single P2-hCD4- and
P2-hCD4+ CD41- CD150+ MEPs displayed plating efficiencies of 33.3% and 28.5% respectively
in these conditions. Alternatively, replating in MethoCult yielded 60.4% and 51.0% plating effi-
ciencies for P2-hCD4- and P2-hCD4+ CD41- CD150+ MEPs respectively (Fig 2G). Under both
culture conditions, approximately 15% of positive wells derived from P2-hCD4+ CD41-
CD150+ MEPs yielded both megakaryocytic and erythroid cells. By contrast, no single
P2-hCD4- CD41- CD150+ MEPs demonstrated dual lineage specification. We therefore estab-
lished that MEP bipotentiality is restricted to the CD41- CD150+ P2-hCD4+ MEP subfraction,
comprising approximately 1% of immunophenotypic MEPs and fewer than 0.05% of total live
cells in E14.5 fetal liver (Fig 2A and 2B).
To fully demonstrate the increased megakaryocytic lineage commitment in E14.5 fetal liver
P2-hCD4+ CD41- CD150+ MEPs compared to their P2-hCD4- counterparts, we cultured both
Enhanced purification of mouse fetal liver hematopoietic progenitors
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Fig 2. Runx1-P2 reporter expression demarcates mono and bipotent subsets in the CD150+ MEP. A-B. Expression of
Runx1-P1-GFP and P2-hCD4 in P1-GFP::P2-hCD4/+ E12.5, E13.5 and E14.5 FL CD41- CD150+ MEPs. A. Representative FACS plots.
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cell types in pro-myeloid medium for 14 hours (Fig 2H and 2I). P2-hCD4+ CD41- CD150+
MEPs produced more MkPs than the P2-hCD4- population, which yielded greater proportions
of erythroid-dominated CD150- MEPs. We therefore demonstrated that the P2-hCD4+ frac-
tion represents a pro-megakaryocyte subpopulation of immunophenotypic MEPs in E14.5 FL.
Runx1-P2-hCD4+ CMPs have enriched multilineage output
Having established that Runx1-P2-hCD4 expression heterogeneity in CD41- CD150+ MEPs is
associated with different lineages, we turned to CD41- CD150+ CMPs. E12.5, E13.5 and E14.5
fetal liver CD41- CD150+ CMPs mostly express Runx1-P1-GFP (81%, 86% and 94% respec-
tively, Fig 3A and 3B). Additionally, most CD150+ CMPs co-express P2-hCD4 (74% in E12.5,
81% in E13.5 and 73% in E14.5 fetal liver). At all three stages, colony-forming output was
skewed in favor of CFU-Ms and away from BFUes in P2-hCD4+ CMPs compared to P2-hCD4-
CMPs (Fig 3C, S3A and S3B Fig). Moreover, CFU-GM output was enriched at E13.5 and
E14.5, and multipotent CFU-GEMM activity was enriched in P2-hCD4+ CMPs at E13.5 com-
pared to the P2-hCD4- populations (Fig 3C, S3B Fig).
OP9 co-culture of the bulk P2-hCD4- and P2-hCD4+ CD41- CD150+ CMP populations
revealed changing lineage output in E12.5, E13.5 and E14.5 fetal liver (Fig 3D and 3E, S3C–
S3F Fig). Notably, pro-GM/anti-Erythroid bias was evident in E14.5 P2-hCD4+ CMPs. Analy-
sis of single co-cultured CMPs (Fig 3F and 3G) confirmed this, as almost 60% of E14.5
P2-hCD4- CMPs produced solely erythroid cells, compared to 12.5% of P2-hCD4+ CMPs. The
granulocyte/monocyte-restricted fraction (“GM only”) represented 3% and 16% of the
P2-hCD4- and P2-hCD4+ CMPs respectively. Megakaryocytic output was similarly enhanced
in P2-hCD4+ CMPs, with 38% possessing Mk-restricted and 9% demonstrating bipotential
megakaryocytic/erythroid (Mk+Ery) activity, (compared to 28% and 6% of P2-hCD4- CMPs).
Importantly, we observed multipotent (balanced Mk+Ery+GM) lineage output in P2-hCD4+
CMPs only, albeit in <10% of positive wells. This suggests multilineage activity is highly
restricted to Runx1-P2-hCD4+ CMPs in E14.5 fetal liver.
Following culture in pro-myeloid medium for 14 hours, the majority of P2-hCD4- CMPs
had acquired a CD34- MEP phenotype (90% of total cells, Fig 3H and 3I). Of these, 71% had
downregulated CD150 expression, suggesting erythroid commitment. By contrast, >20% of
cultured P2-hCD4+ CMPs had acquired an MkP immunophenotype (upregulating CD41),
10% had a CD41- CD150- MEP immunophenotype, and 10% expressed CD16/32, thus acquir-
ing a GMP immunophenotype. Runx1-P2-hCD4+ CMPs can therefore efficiently produce
immunophenotypic MkPs, MEPs and GMPs, whereas P2-hCD4- CMPs appear committed to
the generation of immunophenotypic MEPs.
CD31 expression distinguishes multilineage HPCs from more restricted
progenitors
Having established that Runx1-P2-hCD4+ MEPs and CMPs are enriched in multilineage pro-
genitors, we endeavored to identify cell surface markers which correlated with P2-hCD4
B. Quantitation of the proportions of P1- P2-, P1+ P2-, P1+ P2+ and P1- P2+ MEPs as a percentage of total live red blood cell lysed fetal
liver cells. N = 3 C. Differential CFU-C activity of wild type, P2-hCD4- and P2-hCD4+ E14.5 FL CD41- CD150+ MEPs. N = 6 D-E. Lineage
output of day 7 OP9 co-cultured wild type, P2-hCD4- and P2-hCD4+ CD41- CD150+ MEPs. D. Representative FACS plots of TER119 and
CD41. E. Proportion of erythroid and megakaryocyte cells. N = 4 F-G. Lineage output of single cultured P2- and P2+ MEPs in OP9 co-
cultures (F) and MethoCult semi-solid myeloid culture medium (G). H-I. Short-term (14 hours) differentiation of P2- and P2+ CD41-
CD150+ MEPs in pro-myeloid liquid culture. H. Representative FACS plots of CD16/32/CD34 (top) and CD150/CD41 (bottom) expression
in the LK gate of cultured MEPs. I. Proportions of immunophenotypic MkP, CD41- CD150- MEPs and CD41- CD150+ MEPs in short-term
cultures. N = 5.
https://doi.org/10.1371/journal.pgen.1007127.g002
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expression in E14.5 fetal liver. The aim was to achieve the prospective isolation of these popu-
lations from wild type (WT) or other transgenic mouse lines in the absence of the Runx1-
P2-hCD4 reporter. Firstly, we performed Single Cell RNA Sequencing on CD41- CD150+
P2-hCD4- and P2-hCD4+ MEPs and CMPs. By performing a principal component analysis, we
observed a clear transition in transcriptomic activity from the P2- MEP to the P2+ CMP (S4A
Fig). In particular, erythroid gene expression (for example, Klf1) was highly upregulated in the
P2- MEPs being downregulated with the upregulation of P2-hCD4 and also sharing an inverse
relationship with the megakaryocytic transcription factor Fli1 and the granulocyte/monocyte
transcription factor Spi1 (Pu.1). (Full lists of differentially expressed genes between P2-/+
MEPs and P2-/+ CMPs can be found in S5 Table and S6 Table respectively.)
In order to identify markers which may aid the isolation of P2-hCD4- and P2-hCD4+ MEPs, we
analyzed the expression of various cell surface markers, the aim being to identify genes which are
upregulated or downregulated in some or all P2-hCD4+ MEPs compared to P2-hCD4- MEPs.
Promising candidates included Cd48,Pecam1 (Cd31), Ptprc (Cd45),Eng (Endoglin), Itgb1 (Cd29)
and Tek (Tie2) (S4B Fig). We therefore screened antibodies which had been raised against these
markers and other heterogeneously-expressed markers in fetal liver (S4C Fig).
Promising candidates included the leukocyte common antigen, protein tyrosine phospha-
tase receptor type C (PTPRC) or CD45; CD48 antigen; and platelet/endothelial cell adhesion
molecule 1 (PECAM1) or CD31. All three markers correlated positively with Runx1-P2-hCD4
in LK hematopoietic progenitors (Fig 4A). Immunofluorescence staining, performed on total
fetal liver sections from P1-GFP::P2-RFP E14.5 embryos, demonstrated that although P2-RFP
cells are comparatively rare (2.89% of total DAPI+ cells, Fig 4B, S4D Fig) in E14.5 FL, a large
proportion (64.4%) have cell surface CD31 staining. We therefore proceeded to characterize
CD31 expression in CD41- CD150+ MEPs and CMPs.
In wild type fetal liver, 20% of CD41- CD150+ MEPs expressed CD31 (Fig 4C). By compari-
son,>90% of CD41- CD150+ CMPs were CD31+, although CD31low and CD31high populations
were discernible. We therefore separated CD41- CD150+ CMPs into the 50% lowest and 50%
highest CD31-expressing subfractions (CD31low and CD31high CMPs respectively) for further
characterization.
All MEPs and CMPs expressed CD45 and CD48 (Fig 4C, S4E Fig). Expression of the
RUNX1 target genes Gfi1b and Gfi1 in MEPs and CMPs was also assessed, utilizing the Gfi1b-
GFP and Gfi1-GFP reporter mouse lines (S4F and S4G Fig). The megakaryocytic/erythroid
transcription factor Gfi1b was expressed in all CD41- CD150+ MEPs and CMPs, although the
Gfi1b-GFPmedian fluorescence intensity (MFI) was decreased in some CD31high CMPs (S4F
Fig). In contrast, granulocyte/monocyte-associated Gfi1-GFP was expressed in only 8% of
CD41- CD150+ MEPs and 39% of CD41- CD150+ CMPs, the highest Gfi1-GFP MFI being
associated with high CD31 expression (S4G Fig).
Assessing the CFU-C activity of bulk and single MEP cells in MethoCult culture (Fig 4D,
S4H Fig) revealed that all CFU-Mk and CFU-MkE activity resided with CD31+ MEPs; CD31-
Fig 3. Runx1-P2-hCD4+ CMPs have enriched multilineage output. A-B. Expression of Runx1-P1-GFP and P2-hCD4 in P1-GFP::P2-hCD4/+
E12.5, E13.5 and E14.5 FL CD41- CD150+ CMPs. A. Representative FACS plots. B. Quantitation of the proportions of P1- P2-, P1+ P2-, P1+ P2+ and
P1- P2+ CMPs as a percentage of total live red blood cell lysed fetal liver cells. N = 3 C. Differential CFU-C activity of wild type, P2-hCD4- and
P2-hCD4+ E14.5 FL CD41- CD150+ CMPs. N = 7 D-E. Lineage output of day 7 OP9 co-cultured wild type, P2-hCD4- and P2-hCD4+ CD41- CD150+
CMPs. D. Representative FACS plots of CD11b, GR1, TER119 and CD41. E. Proportion of granulocyte/monocyte, erythroid and megakaryocyte
cells. N = 7 F-G. Lineage output of single cultured P2- and P2+ CMPs in OP9 co-cultures. F. Table of plating efficiency. G. Ternary plots displaying
proportions of granulocyte/monocyte, erythroid and megakaryocyte cells in each positive well for wild type, P2-hCD4- and P2-hCD4+ CD41- CD150+
CMPs. H-I. Short-term (14 hours) differentiation of P2- and P2+ CD41- CD150+ CMPs in pro-myeloid liquid culture. H. Representative FACS plots of
CD16/32/CD34 (top) and CD150/CD41 (middle and bottom) expression in the LK gate of cultured CMPs. I. Proportions of immunophenotypic MkPs,
CD41- CD150- MEPs, CD41- CD150+ MEPs, GMPs, CD41- CD150- CMPs and CD41- CD150+ CMPs in short-term cultures. N = 3.
https://doi.org/10.1371/journal.pgen.1007127.g003
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MEPs possessed CFUe and BFUe activity only. OP9 co-culture confirmed this lineage output
(Fig 4F and 4H; S4I Fig), as CD41+ megakaryocyte cells were absent in CD31- MEP co-cultures
but present in 7% of positive wells derived from CD31+ MEPs (S4I Fig). This suggested that
CD31+ MEPs possess some Mk lineage specificity (albeit in only 7–20% of cells), whereas
CD31- MEPs solely constitute erythroid progenitors.
Erythroid lineage output was enriched in CD31low CMPs compared to CD31high CMPs
(Fig 4E, 4G and 4I; S4J Fig); 20% of CD31low CMPs produced BFUes and 54% of single co-
cultured cells yielded solely TER119+ erythroid cells. CD11b+ Gr1+ granulocyte/monocyte
and CD41+ megakaryocyte cell output was enhanced considerably in CD31high CMPs. Inter-
estingly, although CFU-GEMM activity was enriched in CD31high CMPs, the proportion of
positive co-cultured wells yielding megakaryocyte/erythroid/granulocyte/monocyte cells was
higher for CD31low CMPs. This was probably due to the overall plating efficiencies being
higher for CD31high CMPs. Therefore, both CD31low CMPs and CD31high CMP populations
are heterogeneous, albeit skewed towards erythroid and GM/megakaryocytic specification
respectively.
The short-term culture of these populations revealed hierarchical relationships; CD31+
MEPs gave rise to CD31- MEPs and MkPs, whereas CD31- MEPs rapidly downregulated
CD150 (S4K and S4M Fig). The CD31low CMPs are skewed to a pro-MEP fate, whereas
CD31high CMPs efficiently produce GMPs and CD31+ MEPs (S4L and S4N Fig). CD31low
CMPs therefore comprise a more advanced pro-erythroid fraction, but can also produce
CD31high CMPs, suggesting some granulocyte/monocyte commitment.
As previously indicated, the provenance of the fetal liver myeloid progenitors is not
entirely clear. Following initial fetal liver colonization at E11.5, the HSCs expand exponen-
tially and the numbers of repopulating units (per embryo equivalent) peak by E16, as fetal
bone marrow colonization is underway (having begun from E15) [29,30,44]. To add weight
to the hypothesis that the CD150+ MEP and CMP populations are fetal liver HSC-derived,
we analyzed these fractions in E16.5 fetal liver. Firstly, upon analyzing the LK hematopoietic
progenitor compartment of the Runx1 P1-GFP::P2-hCD4E16.5 fetal liver, we observed that
the frequencies of P2+/- CD41- CD150+ MEPs and CMPs closely resembled that observed in
E14.5 fetal liver (S5A and S5B Fig). Upon isolating these populations, we observed that the
P2+ CD41- CD150+ MEPs and CMPs displayed decreased erythroid and increased megakar-
yocytic/GM output compared to the P2- fractions (S5C–S5H Fig). We also confirmed that
Runx1 P2-hCD4 expression correlated well with CD31 expression in the E16.5 fetal liver LK
fractions (S5I-J) and that wild type E16.5 CD31+/- MEPs and CD31low/high CMPs displayed
similar lineage specificities, particular concerning erythroid output, compared to their P2+/-
equivalents (S5K-P). This therefore suggests that similar MEP and CMP populations can be
discerned in E16.5 fetal liver as in E14.5 fetal liver and therefore that the hematopoietic hier-
archy is maintained 5 days after fetal liver colonization, even after the shift to bone marrow
colonization has begun.
Fig 4. CD31 expression distinguishes multilineage HPCs from more restricted progenitors. A. Representative FACS plots of CD45,
CD31 and CD48 expression in P1-GFP::P2-hCD4/+ E14.5 FL P2-hCD4- and P2-hCD4+ LK cells. B. Representative micrographs of DAPI,
P2-RFP, CD31 and P1-GFP Immunofluorescence staining in Runx1-P1-GFP::P2-RFP E14.5 fetal liver. Examples of P1-GFP- P2-RFP+
(white arrows), P1-GFP+ P2-RFP+ (white arrowheads) and P1-GFP+ P2-RFP- (white asterisks) cells are indicated. C. Representative FACS
plots of CD31/CD45 expression in wild type E14.5 fetal liver CD41- CD150+ MEPs and CMPs. D-E. Differential CFU-C activity in wild type
E14.5 fetal liver CD31-/+ MEPs (D, N = 7) and CD31low/high CMPs (E, N = 6). F-I. Lineage output of OP9 co-cultured MEPs and CMPs. F.
Representative FACS plots of TER119 and CD41 expression of day 7 OP9 co-cultured MEPs. G. Representative FACS plots of CD11b,
GR1, TER119 and CD41 expression of day 7 OP9 co-cultured CMPs. H. Proportion of TER119+ erythroid cells and CD41+ megakaryocyte
cells in day 7 OP9 MEP co-cultures. I. Proportion of granulocytes/monocytes, erythroid cells and megakaryocytes in day 7 OP9 CMPs co-
cultures. N = 8.
https://doi.org/10.1371/journal.pgen.1007127.g004
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Runx1-null CD31low CMPs have impaired erythroid cell production
Defining restricted fetal liver hematopoietic progenitor cell compartments should provide the
ability to identify the impact of genetic alterations with greater precision. For example,
Runx1-flox::Vav1-Cre conditional knockout mice display impaired fetal liver erythroid and
megakaryocytic maturation (S6A–S6H Fig).
The absence of RUNX1 protein in Runx1-flox/flox::Vav1-Cre (Runx1-del/del, S6A Fig)
apparently caused a block in the upregulation of TER119 expression. Consequently, there was an
accumulation of the immature S0-S2 erythroid lineage subsets, but a decrease in the CD71high
TER119high S3 population (S6B-E) [45]. Following megakaryocytic culture, Runx1-del/del fetal
liver samples produced more CD41high megakaryocytes than their WT and Runx1-del/+ litter-
mates, but the majority of these did not upregulate CD42d, reflecting the previously described
megakaryocytic maturation block (S6F and S6G Fig). This was confirmed by the complete
absence of morphologically mature megakaryocytes, following staining with May-Gru¨nwald
Giemsa reagent (S6H Fig). This megakaryocyte maturation block is reminiscent of Familial Plate-
let Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML), almost exclusively the
result of germline heterozygous RUNX1 gene mutations/deletions [46,47].
To further investigate the impact of the absence of RUNX1, we performed a detailed char-
acterization of the hematopoietic progenitor composition of Runx1-del/del E14.5 fetal liver
using our CD31 staining protocol and compared it to wild type and Runx1-del/+ heterozygous
littermates (Fig 5A–5C, S7A and S7B Fig). CD41- CD150+ CD31+/- MEP and CD31low/high
CMP populations were all expanded in Runx1-del/del fetal liver, as was the pro-GM CD41-
CD150- CMP fraction (Fig 5B–5C, S7B Fig). By contrast, pro-erythroid CD41- CD150- MEPs
were depleted (Fig 5A, S7B Fig), suggesting the absence of RUNX1 may block erythroid differ-
entiation during fetal liver hematopoiesis.
Assessment of CFU-C activities (S7C–S7F Fig) uncovered a modest increase in CFUe pro-
duction by Runx1-del/del CD41- CD150+ CD31+ MEPs but decreased CFU-MkE and CFU-
GEMM activity in Runx1-del/del CD41- CD150+ CD31high CMPs. Total CFU-Mk output did
not appear to be decreased, but defective megakaryocytic maturation was evident as morpho-
logically mature CFU-Mks were absent from Runx1-del/del hematopoietic progenitor cultures
(S7E and S7F Fig).
Bulk OP9 co-culture revealed decreased mature TER119+ erythroid cell production by
Runx1-del/del CD31low CMPs and CD31-/+ MEPs, but not CD31high CMPs (Fig 5D and 5E,
S7G and S7K Fig), confirming an erythroid maturation block. Runx1-del/del CD31low CMPs
had increased CD41+ megakaryocytic output, in line with the previously reported increased
proliferation/reduced maturation in this lineage [48]. However, this did not answer the ques-
tion of whether lineage specification was altered by the absence of RUNX1 causing a perturba-
tion of the numbers of pro-erythroid, pro-megakaryocyte and/or pro-granulocyte/monocyte
progenitors in hematopoietic progenitor pools.
To address this question, we performed single cell OP9 co-cultures and observed similar
total plating efficiencies for wild type, Runx1-del/+ and Runx1-del/del populations (Fig 5F).
Whereas>50% of wild type and Runx1-del/+ CD31low CMPs solely produced TER119+ Ery-
throid cells, this was reduced 4-fold in Runx1-del/del CD31low CMPs (Fig 5G and 5H, S7L Fig),
with a concurrent increase in pro-GM progenitors. Erythroid cells were more modestly reduced
in CD31high CMP cultures (S7M–S7O Fig), but this was not very impactful as the population
has a lower pro-erythroid pool in wild type fetal liver compared to its CD31low counterpart.
Moreover, the Median Fluorescent Intensity of the TER119+ erythroid cells was decreased in
Runx1-del/del CD31low CMP cultures compared to that of wild type littermates (S7P Fig). This
confirmed that the proportion of pro-erythroid progenitors residing in the fetal liver CD31low
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CMP fraction is diminished in Runx1-null E14.5 embryos, and that differentiation of these pro-
genitors is impaired.
A key advantage of identifying these highly purified CD31low and CD31high CMP fractions
in Runx1 null fetal liver is the ability to analyze underlying cell-intrinsic changes driving the
lineage specification and maturation defects with greater precision, particularly at a transcrip-
tome level. We therefore analyzed the expression of key HSC and lineage-associated transcrip-
tional regulators in wild type, Runx1-del/+ and Runx1-del/del CD31low and CD31high CMPs
(S7Q Fig). One key observation was that several key HSC and megakaryocyte/erythrocyte-
associated transcription factors (Tal1, Gfi1b and Klf1) were downregulated in wild type
CD31high CMPs compared to wild type CD31low CMPs, reflecting the megakaryocytic/ery-
throid lineage commitment which accompanies CD31 downregulation in the CMP compart-
ment and demonstrating that CD31low and CD31high CMPs represent transcriptionally
distinct progenitor subsets.
Notably, expression of Tal1, Gfi1b and Klf1 did not differ between wild type, Runx1-del/+
and Runx1-del/del CD31high CMPs. However, they were substantially downregulated in
Runx1-del/del CD31low CMPs compared to their wild type and Runx1-del/+ equivalents. In
fact, the transcription factors Tal1, Gfi1b, Klf1 and Gata2, plus the megakaryocytic/erythroid
lineage markers Itga2b, Pf4 and Epor (S7R Fig), were all expressed at comparable levels in
Runx1-del/del CD31low CMPs to CD31high CMPs (of all genotypes). This supports the hypothe-
sis that the absence of RUNX1 results in a differentiation block between the CD31high and
CD31low CMPs. Additionally, it indicates that the megakaryocytic/erythroid maturation
defects are established even at this early stage, with a failure to upregulate key maturation-asso-
ciated transcripts.
Interestingly, unlike the pro-erythroid transcription factor Klf1, the pro-megakaryocytic
Fli1 and the pro-GM Spi1 and Gfi1 were not significantly different in CD31low and CD31high
CMPs; nor were they impacted by the absence of RUNX1. This may indicate that commitment
to the erythroid lineage is the default position in the FL CD31high-to-CD31low CMP transition,
which was hindered in the absence of RUNX1. We therefore clearly demonstrate the benefits
of isolating highly purified myeloid progenitors to aid in the understanding of the mechanistic
basis of congenital hematopoietic defects in the fetal liver.
Runx1-P1-MRIPV CD31high CMPs have impaired Mk specification
We recently reported that deleting the RUNX1C isoform in adult mice, whilst maintaining
total RUNX1 expression, resulted in mild thrombocytopenia, due to impaired megakaryocytic
specification but with normal megakaryocyte maturation. To achieve this we utilized the
Runx1-P1-MRIPV line, in which the P1-encoded RUNX1C isoform is replaced by the P2-
encoded RUNX1B isoform [39]. Given the contrast between this phenotype and that of the
Runx1-del/del adult model, we decided to interrogate P1-MRIPV fetal liver hematopoiesis.
Having confirmed P1-MRIPV/MRIPV and P1-MRIPV/+ fetal liver cells maintain RUNX1
protein expression at wild type levels (S8A Fig), we examined erythroid and megakaryocytic
Fig 5. Runx1-null CD31low CMPs have impaired erythroid cell production. A-C. Identifying CD31-expressing CD41- CD150+ MEPs and CMPs
in Runx1 wild type, heterozygous (Del/+) and null (Del/Del) E14.5 fetal liver. Representative FACS plots of CD150/CD41 and CD31/CD45
expression in MEPs (A) and CMPs (B). C. Quantitation of CD31-/+ MEPs and CD31low/high CMPs. N = 6 D-E. Lineage output of OP9 co-cultured
Runx1 wild type, heterozygous and null CD31low CMPs. D. Representative FACS plots of CD11b, GR1, TER119 and CD41 expression of day 7
OP9 co-cultured CD31low CMPs. E. Proportion of granulocyte/monocyte, erythroid and megakaryocyte cells in day 7 OP9/CD31low CMPs co-
cultures. N = 4 F-H. Lineage output of single OP9 co-cultured Runx1 wild type, heterozygous and null CD31low and CD31high CMPs. F. Plating
efficiency of CD31low and CD31high CMPs. G. Ternary plots displaying proportions of granulocyte/monocyte, erythroid and megakaryocyte cells in
each positive well for CD31low CMPs. H. Proportions of unilineage (Ery, Mk and GM only) and multilineage (Mk+Ery, Mk+GM, Ery+GM and
GEMM) wells derived from CD31low CMPs. N = 4.
https://doi.org/10.1371/journal.pgen.1007127.g005
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maturation in these samples (S8B–S8G Fig). Unlike in Runx1-null fetal liver, P1-MRIPV/
MRIPV fetal liver displayed only a modest increase in the CD71-/low TER119- S0 fraction and
corresponding decrease in the CD71high TER119high S3 fraction. This suggested that the
absence of RUNX1C/overexpression of RUNX1B does not significantly impact erythroid mat-
uration (S8B–S8E Fig). Following megakaryocyte culture, we observed that megakaryocytic
maturation was also unimpaired, as the proportions of mature CD41high CD42d+ megakaryo-
cytes were similar in wild type, P1-MRIPV/+ and P1-MRIPV/MRIPV cultures (S8F and S8G
Fig).
We next proceeded to characterize fetal liver myeloid hematopoietic progenitor compart-
ments using our CD31 staining protocol (Fig 6A–6C, S9A and S9B Fig). The impact of deleting
RUNX1C alone was far more restricted, the CD41- CD150+ CD31- MEP being the only
expanded population identified in P1-MRIPV/MRIPV fetal liver (Fig 6A–6C). As the CD31-
MEP is highly erythroid-biased, we investigated whether P1-MRIPV/MRIPV fetal liver progen-
itors displayed pro-erythroid/anti-megakaryocytic bias. CFU-C assays revealed increased
CFUe activity in the P1-MRIPV/MRIPVCD31+ MEP, but decreased CFU-Mk and increased
CFU-M activity in the CD31high CMP (S9C–S9F Fig).
OP9 co-culture suggested the absence of RUNX1C did not impair the lineage output of
CD31- or CD31+ MEPs (S9G–S9I Fig). Whilst the P1-MRIPV/MRIPVCD31low CMP was
modestly affected, substantially decreased CD41+ megakaryocyte output and increased
CD11b+ GR1+ granulocyte/monocyte output were observed for P1-MRIPV/MRIPVCD31high
CMPs (Fig 6D–6G). We therefore hypothesized that the dominant impact of deleting
RUNX1C (or overexpressing RUNX1B) on megakaryocytic versus granulocyte/monocyte
specification occurs in the CD31high CMP fraction.
This hypothesis was confirmed through short-term culture of the CMP populations (S9J–
S9M Fig), as P1-MRIPV/MRIPVCD31high CMPs produced fewer MkPs and more GMPs than
their wild type counterparts, but the lineage specification of CD31low CMPs was largely unaf-
fected. Therefore, in contrast to the impaired erythroid specification of Runx1-del/del CD31low
CMPs, P1-MRIPV/MRIPVCD31high CMPs display impaired megakaryocytic specification.
This demonstrates that the RUNX1B and RUNX1C isoforms have distinct roles during fetal
liver hematopoiesis, akin to adult bone marrow hematopoiesis, which can be uncovered using
our enhanced fetal liver HPC purification strategies.
Discussion
Bone marrow myeloid hematopoietic progenitor cells have been extensively characterized,
including the recent demonstration that immunophenotypically similar CMPs can be sepa-
rated into distinct PU.1-eYGPhigh GATA1-mCherry- pro-granulocyte/monocyte and
PU.1-eYFPlow GATA1-mCherry+ pro-megakaryocyte/erythroid fractions [40]. This therefore
confirms that lineage fate decisions had commenced upstream of the CMPs in ancestral
HSPCs. By comparison, the delineation of myeloid lineage-restricted hematopoietic progeni-
tors in fetal liver lags critically behind. We therefore attempted to further compartmentalize
the immunophenotypic MEP and CMP fractions to provide a more detailed hematopoietic
hierarchy (summarized in Fig 7A). CD55 and CD150 were obvious lead candidates, as CD55
was successfully utilized by Guo et al to subdivide adult CMPs into pro-megakaryocyte/ery-
throid and pro-granulocyte/monocyte fractions [41]; additionally, CD150 is a well-established
pro-megakaryocytic/erythroid and HSC marker [5,32,43,49,50]. We observed that the entirety
of megakaryocytic/erythroid bipotential and granulocyte/monocyte/megakaryocyte/erythro-
cyte multipotential CFU-C output resides respectively in the CD55+ CD150+ MEP and CD55+
CD150+ CMP fetal liver fractions. However, the CFU-Mk and CFU-MkE output of CD55+
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CD150+ MEPs remained low (~5%), highlighting the need for further refined hematopoietic
progenitor subfractionation.
For this, we identified distinct myeloid hematopoietic progenitor subsets on the basis of
P2-hCD4 expression in our Runx1 P1-GFP::P2-hCD4 reporter mouse. To broaden the applica-
tion of this finding, and not rely on the P1-GFP::P2-hCD4 reporter mouse, we searched for cell
surface markers which correlated with P2-hCD4 expression. Following a screen of markers
associated with heterogeneous fetal liver expression or multipotency/lineage specification in
bone marrow hematopoietic progenitors [51], we identified CD31, CD45 and CD48 as strong
candidates. Downregulation of the pan-leukocyte marker, CD45 [52,53], and the bone marrow
hematopoietic progenitor, lymphocyte and macrophage-associated CD48 [49,54–56] upon
fetal liver erythroid commitment concurs with adult bone marrow erythroid progenitor speci-
fication [51]. CD31, meanwhile, is expressed in endothelial progenitor cells and their mature
progeny [57–60]. CD31-null mice are viable and do not exhibit obvious vascular defects; none-
theless CD31 plays significant roles in vascular remodeling and tumor metastatic progression
as well as in adhesion, survival, migration and activation of hematopoietic cells [61–70]. In
E14.5 fetal liver, CD31 is predominantly expressed in cells lining the hepatic vessels, but also in
some Runx1+ hematopoietic stem and progenitor cells. We observed CD31 expression was
highly enriched in the fetal liver myeloid progenitors with the greatest granulocyte/monocyte
and megakaryocytic output. This concurs somewhat with the observation that in fetal liver and
bone marrow, the entire multilineage LSK hematopoietic stem and progenitor cell fraction
expresses CD31 [57,71,72]. Contrastingly, the bone marrow LK CD31+ fraction was deficient
in granulocyte/monocyte output, possessing chiefly short-term erythroid repopulating cells,
whereas we demonstrate here that erythroid lineage commitment in fetal liver coincides with
CD31 downregulation. This suggests CD31-expressing short-term progenitors are not equiva-
lent throughout mouse ontogeny. The shift from CD31+ pro-GM/megakaryocytic fetal liver
hematopoietic progenitors to bone marrow erythroid progenitors may reflect distinct interac-
tions with their respective niches. CD31-null adult mice have more steady state circulating
progenitors, as hematopoietic progenitors fail to migrate across the bone marrow vasculature
[68]. This phenotype was observed whether CD31 was deleted in hematopoietic or endothelial
cells or both. The retention of the numerous, highly clonogenic CD31- fetal liver erythroid pro-
genitors in their niche may be less crucial than for CD31+ bone marrow erythroid progenitors,
which are replaced less frequently by more quiescent precursors.
High CD31 expression in fetal liver pro-GM/megakaryocytic progenitors reinforces a phe-
notypic link between megakaryocytes and endothelial cells, which co-express numerous recep-
tors, transcription factors and other signaling-associated factors [73]. The similarities become
even more pronounced when considering hemogenic endothelium, which produces HSCs
through EHT, due to the elevated expression of hematopoietic regulators which drive this pro-
cess [74–76]. Megakaryocytes and endothelial cells are spatially close in hematopoietic vascular
niches, their interactions conducted partially by CD31 [77]. Indeed, CD31’s absence impacts
multiple aspects of megakaryopoiesis. It would therefore be worthwhile to determine whether
CD31 deficiency impacts ancestral HPCs as well as their megakaryocytic progeny. Hematopoi-
etic progenitor cell retention in the fetal liver vascular niche may consequently be severely
Fig 6. Runx1-P1-MRIPV CD31high CMPs have impaired Mk specification. A-C. CD31-expressing CD41- CD150+ MEPs and
CMPs in Runx1 wild type, P1-MRIPV/+ and P1-MRIPV/MRIPV E14.5 fetal liver. Representative FACS plots of CD150/CD41 and
CD31/CD45 expression in MEPs (A) and CMPs (B). C. Quantitation of CD31-/+ MEPs and CD31low/high CMPs. N = 7 D-G. Lineage
output of OP9 co-cultured Runx1 wild type, P1-MRIPV/+ and P1-MRIPV/MRIPV CD31low and CD31high CMPs. D-E. Represent-
ative FACS plots of CD11b/GR1 and TER119/CD41 expression of day 7 OP9 co-cultured CD31low (D) and CD31high CMPs (E).
F-G. Proportions of granulocyte/monocyte, erythroid and megakaryocytic cells in day 7 OP9 co-cultured CD31low (F) and
CD31high (G) CMPs. N = 5.
https://doi.org/10.1371/journal.pgen.1007127.g006
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impaired [68], potentially adding a new functional dimension to CD31 expression on CMPs
and MEPs, as well as an immunophenotyping application.
One of the questions raised by our studies was whether the immunophenotypic CMP com-
partment actually contains single progenitor cells with the ability to produce granulocyte/mono-
cyte, megakaryocyte and erythroid cells, thereby being defined as true Common Myeloid
Progenitors. The alternative is that the CMP compartment solely comprises a heterogeneous pop-
ulation of monopotent or bipotent progenitors. Our single cell myeloid OP9 co-culture assays
offer evidence that a small minority (<20%) of single isolated CMPs yield megakaryocytes, eryth-
rocytes and granulocytes/monocytes, as would be expected for a true CMP. Therefore, we provide
evidence that supports the existence of the CMP as a rare population within the fetal liver.
The CMP appears to be far scarcer than previously understood and it is likely that the LSK
Multipotent Progenitor fractions may dominate in terms of common myeloid ancestry, partic-
ularly as they yield greater numbers of CFU-GEMMs than immunophenotypic CMPs. Indeed,
we observed that fetal liver LSK HSCs and MPPs appeared to be the ancestors of the LK
hematopoietic progenitors, at least in vitro. Contrastingly, we were unable to reproduce a simi-
lar myeloid progenitor hierarchy following culture of yolk sac cells. Nonetheless, several stud-
ies have suggested that at least some definitive hematopoietic stem and progenitor cells located
in the embryo proper do not arise de novo, but instead originate from the yolk sac [75,78–80].
Therefore, it is possible that EMPs could be responsible to some extent for the establishment of
a fetal liver hematopoietic progenitor hierarchy, including our populations of interest: the
CD150+ MEPs and CMPs. Our results would suggest that this is only achieved after fetal liver
colonization and differentiation in this supportive niche, yielding fetal liver hematopoietic
stem and progenitor cells which, in turn, produce myeloid-restricted progenitors.
Our intent in this study was to delineate different fetal liver myeloid progenitor compart-
ments, in order to provide a method to examine homeostatic developmental hematopoiesis
and hematopoietic disease models. Indeed chromosomal translocations such as AML1-ETO,
PML-RARA and CBFβ-MYH11, which cause childhood Acute Myeloid Leukemia (AML), fre-
quently arise in utero as demonstrated by the high prevalence of such mutations in neonatal
blood samples [34–36], and may therefore impact fetal hematopoiesis. Furthermore, Ye et al
demonstrated that the initiation of AML requires partial myeloid differentiation by trans-
formed CMPs to GMPs, highlighting how an understanding of the myeloid progenitor hierar-
chy facilitates examination of the origins and progression of malignant hematopoietic
disorders [16]. To demonstrate the application of our fetal liver myeloid progenitor scheme,
we analyzed the impact of deleting Runx1 (a mutation which causes a megakaryocytic differen-
tiation block comparable to FPD/AML [38,46,48]) on the specification and differentiation of
these compartments. Akin to Behrens et al [81] in the adult, we observed deleting Runx1
causes a block in fetal liver erythroid differentiation and pinpointed this block to CD150
downregulation in immunophenotypic MEPs (Fig 7B). We also observed decreased erythroid
specification in the Runx1-del/del CD150+ CD31low CMP fraction, and determined that this
may be due to a failure to upregulate an erythroid transcriptional network in the transition
from CD31high to CD31low CMP. We are therefore able to gather a substantial amount of phe-
notypic information and also gain mechanistic insights from transcriptome analyses.
Fig 7. Distinct subsets within the classically defined CMP and MEP compartments can be segregated on the basis of
CD55, CD150 and CD31 expression. A-B. Proposed models of fetal liver myeloid progenitor hierarchy. A. In wild type fetal liver,
commitment to the erythroid lineage correlates with downregulation of the Runx1b and Gfi1 TFs, plus the cell surface markers
CD150, CD31, CD45 and CD48. B. RUNX1-null fetal liver hematopoietic progenitors have impaired Mk and erythroid
differentiation (dark blue bars), whereas RUNX1C-null (P1-MRIPV) hematopoietic progenitors have impaired megakaryocyte
specification, displaying enhanced erythroid and granulocyte/monocyte commitment (light blue arrows).
https://doi.org/10.1371/journal.pgen.1007127.g007
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We also evaluated the impact of removing the dominant RUNX1C isoform on fetal liver
myelopoiesis. As we previously described in the adult, RUNX1C-null P1-MRIPV/MRIPVmice
do not appear to have impaired megakaryocytic/erythroid differentiation [39]. Nonetheless,
the fetal liver CD150+ CD31- MEP fraction was expanded, partially recapitulating the Runx1-
null erythroid lineage phenotype. However, P1-MRIPV/MRIPV fetal liver had reduced mega-
karyocytic specification, with the CD150+ CD31high CMP-to-MkP transition being the most
impaired pathway. We did not observe this in Runx1-null fetal liver; in fact megakaryocytic
output increased in the absence of total RUNX1, as observed in adult hematopoiesis [39,81].
This difference may explain the apparently contradictory finding by Kuvardina et al [82] that
RUNX1 promotes megakaryocytic specification; RUNX1C may have a non-redundant func-
tion in megakaryocytic specification, whereas RUNX1B is either necessary or sufficient for
megakaryocytic and erythroid maturation. Our myeloid hematopoietic progenitor scheme has
allowed us to identify the cells of interest which perpetuate this hematological imbalance. Such
a technique could therefore be applied to understanding the cells of origin in familial thrombo-
cytopenia, or a recently described case of RUNX1-deleted Congenital Amegakaryocytic
Thrombocytopenia [83]. Moreover, our new protocol for prospective isolation of myeloid
hematopoietic progenitors could be applied more broadly to other congenital or somatic
genetic disorders which manifest in utero, as well as to analyzing lineage fate decisions in nor-
mal fetal liver hematopoiesis.
Materials and methods
Animal husbandry, timed matings and tissue collection
Runx1-P1-GFP::P2-hCD4,Runx1-P1-MRIPV, Runx1-flox::Vav1-Cre, Gf1i-GFP and Gfi1b-GFP
mice have been described [17,38,39,84,85]. Dual-reporter Runx1-P1-GFP::P2-RFP chimeric
mouse lines were generated by transfecting P1-GFP embryonic stem cells (ESCs) [17] with a
P2-RFP targeting construct [86,87], screening for heterozygote knock-in lines targeting the
same allele, and injecting correctly targeted ESCs into C57BL6J blastocysts.
Runx1 P1-GFP::P2-hCD4,P1-GFP::P2-RFP, P1-MRIPV, Runx1 flox::Vav1-Cre, Gfi1-GFP
and Gfi1b-GFPmice were backcrossed with C57BL/6 mice for at least 10 generations and were
housed in specific pathogen free cages with environmental enrichment. To trace Runx1 pro-
moter activity, timed matings were set up between Runx1 P1-GFP::P2-hCD4 or P1-GFP::
P2-RFP male mice and wild type (WT) ICR female mice. To produce Runx1 P1-MRIPV/
MRIPV or Runx1 flox/flox::Vav1-Cre embryos (plus wild type and heterozygous control litter-
mates), timed matings were set up between Runx1 P1-MRIPV/+ mice or between Runx1 flox/
+::Vav1-Cre males and Runx1 flox/+ females. To trace Gfi1 and Gfi1b expression, timed mat-
ings were set up between Gfi1-GFP or Gfi1b-GFPmale mice and WT ICR female mice.
Embryos were harvested on embryonic day (E) 12.5, 13.5, 14.5 or 16.5 and the fetal livers dis-
sected for flow cytometric or histological analysis. For yolk sac experiments, embryos were
harvested on E9.5 and the yolk sacs dissected for flow cytometric analysis, or for explant or
pro-myeloid culture (as described below). Approximately 104 cells were kept for genotyping
by PCR (oligonucleotides listed in S1 Table).
All animal work was performed under regulations governed by UK Home Office Legisla-
tion under the Animals (Scientific Procedures) Act 1986 and was approved by the Animal
Welfare and Ethics Review Body of the Cancer Research UK Manchester Institute.
Fluorescence Activated Cell Sorting (FACS)
Details of FACS reagents and combinations used for each analysis are listed in S2 and S3
Tables. Prior to flow sorting or analysis of HPCs in E12.5, E13.5, E14.5 or E16.5 fetal liver, red
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blood cell lysis was performed as described [18]. Dead cells were excluded using 1μg/ml
Hoechst 33258 (ThermoFisher Scientific); gates were positioned based on Full Minus One
controls. Cells were analyzed using a LSR-II or LSR-II Fortessa analyzer (BD Biosciences) or a
NovoCyte (ACEA Biosciences Inc.). Cells were sorted using a FACSAria-II, FACSAria-III or
Influx cell sorter (BD Biosciences).
Cell culture
OP9 co-culture. Mouse OP9 stromal cells were maintained in culture as described [18].
For bulk myeloid OP9 co-culture, fetal liver hematopoietic progenitors (2000 cells/ml) were
seeded on OP9 cells (5000/ml). Myeloid OP9 co-culture medium has been described [18]. For
single cell OP9 co-culture, single hematopoietic progenitor cells were directly sorted into
96-well plate wells containing 100μl myeloid OP9 co-culture medium and approximately 500
OP9 cells. Co-cultured cells were incubated in 5% CO2 and 5% O2 at 37˚C for 7 days (5 days
for single MEPs) before positive wells were assessed by microscopy and FACS analyzed for
myeloid cell surface marker expression (TER119, CD41, GR1, CD11B, CKIT as detailed in S3
Table). For single cell cultures, the threshold for being counted as containing erythroid, mega-
karyocytic or granulocytic/monocytic cells was >2% TER119+, CD41+ or CD11b+ GR1+ cells
respectively.
Hematopoietic colony-forming assays. Methylcellulose-based CFU-C assays were per-
formed by plating 200 MEPs, 50 CMPs, 50 LSK HSPCs, 200 GMPs, 500 MkPs or 1000 cKit-
cells per dish in MethoCult GF M3534 (StemCell Technologies) supplemented with Penicillin-
Streptomycin (100U/ml Penicillin, 100μg/ml Streptomycin, Sigma-Aldrich), 2U/ml erythro-
poietin (Eprex, Janssen-Cilag Ltd), medium conditioned by a cell line producing thrombo-
poietin (TPO) (1% final concentration), 5ng/ml IL11 (R&D Systems) and 10ng/ml Flt3 Ligand
(Peprotech). For single cell CFU-C assays, single MEPs were directly sorted into 96-well plate
wells containing 100μl MethoCult media as described above. CFUes were scored after 3–4
days and other colonies after 8 days under a microscope (DM IL, Leica).
Short-term culture of fetal liver hematopoietic stem and progenitor cells. Purified fetal
liver MEPs, CMPs and LSK hematopoietic stem/progenitor cells were cultured at 37˚C in 5%
CO2 and atmospheric O2 for 14 hours (MEPS and CMPs) or 20 hours (LSK HSPCs) in pro-mye-
loid medium (IMDM supplemented with 10% Fetal Bovine Serum (FBS) for Mouse Myeloid Col-
ony-Forming Cells (StemCell Technologies), 10% Protein-free hybridoma medium (PFHM-II,
Gibco), 180μg/ml Transferrin (Roche Diagnostics), 0.45mM monothioglycerol (MTG, Sigma-
Aldrich), 50ng/ml ascorbic acid (Sigma-Aldrich), 2mM L-glutamine (ThermoFisher Scientific),
Penicillin-Streptomycin, 4U/ml erythropoietin, 5ng/ml IL11, 10ng/ml IL6 (R&D Systems), 10ng/
ml M-CSF (R&D Systems) and medium conditioned by cell lines producing IL3, GMCSF, TPO
and Stem Cell Factor (SCF) (1% final concentration). Cells were then harvested and FACS ana-
lyzed for hematopoietic stem/progenitor markers as described in S3 Table.
Short-term culture of yolk sac cells. Yolk sacs were dissected from E9.5 embryos and
either cultured as explants as described [88] or dissociated with 1mg/ml Collagenase-Dispase/
Phosphate Buffered Saline (PBS) (Roche) at 37˚C for 20 minutes. Yolk sac cell suspensions
were then either FACS analyzed for hematopoietic stem/progenitor markers as described in S3
Table (day 0) or cultured in pro-myeloid medium (see above) for 24 or 48 hours. After 48
hours, explant-cultured yolk sac cells were dissociated by trypsinization and either FACS ana-
lyzed for hematopoietic stem/progenitor markers (see S3 Table) immediately or following cul-
ture in pro-myeloid medium for a further 24 hours.
Megakaryocyte culture of fetal liver. Following red blood cell lysis, unfractionated fetal
liver cells were cultured at 37˚C in 5% CO2 and atmospheric O2 for 7 days at a density of 10
5
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cells per ml in pro-megakaryocyte medium (IMDM supplemented with 10% FBS for Mouse
Myeloid Colony-Forming Cells, 2mM L-glutamine, Penicillin-Streptomycin, 0.45mM MTG,
20ng/ml IL6, 50ng/ml IL11 and medium conditioned by cell lines producing IL3 and TPO
(1% final concentration). Cells were then harvested and FACS analyzed for CD41 and CD42d
expression as described in S3 Table.
Cytospin analysis
Up to 50,000 cultured fetal liver cells were suspended in 150μl PBS and immobilized on twin
frosted glass microscope slides (Fisher Scientific) by cytospin at 200rpm, low acceleration for 5
minutes in a Shandon Cytospin3 (Thermo Scientific). Air-dried slides were submerged in
May-Gru¨nwald Eosin methylene blue Q Path stain (VWR) for 3 minutes, rinsed in tap water
and submerged in 5% Giemsa’s stain (VWR) for 20 minutes. Slides were subsequently air
dried, mounted and scanned using the Pannoramic 250 Flash III (3DHISTECH). Images were
acquired with the Pannoramic 250 software and analyzed with the Pannoramic Viewer soft-
ware (3DHISTECH).
Immunofluorescent staining and imaging of fetal liver sections
Dissected fetal livers were fixed in 4% Paraformaldehyde (PFA) overnight, before they were
soaked in 30% sucrose and mounted in OCT compound. 10μm sections were prepared using a
cryostat. The sections were incubated in blocking buffer (PBS with 10% FBS, 0.05% Tween20
and 10% goat serum (DAKO)) for 1 hour before the sections were incubated with primary
antibodies at 4˚C overnight in blocking buffer.
Primary antibodies used in this study were rabbit anti-GFP (598, polyclonal, MBL) (1/200);
and purified rat anti-mouse CD31 (553370, MEC13.3, BD Biosciences) (1/100).
Sections were washed three times in PBST (PBS with 0.05% Tween20) for 15 minutes each
and then incubated with fluorochrome-conjugated secondary antibody at room temperature
for 1 hour.
Secondary antibodies used in this study include Alexa Fluor 488 Goat Anti-Rat IgG
(A11006, Life Technologies); and Alexa Fluor 647 F(ab’)2 Fragment of Goat Anti-Rabbit IgG
(H+L) (A21246, Life Technologies). All secondary antibodies were used at 1/400 dilution.
Sections were further washed three times in PBS and mounted using Prolong Gold anti-
fade medium with DAPI (Life Technologies). Images (of Alexa Fluor 488, Alexa Fluor 647,
DAPI and endogenous RFP) were taken using a low-light time lapse microscope (Leica) using
the Metamorph imaging software and processed using ImageJ.
Western blot analysis
Whole cell protein extracts, purified using RIPA lysis buffer, were quantitated by the Bradford
assay (Protein Assay Dye Reagent, Bio-Rad) on the Glomax Multi Detection System (Promega)
and loaded alongside the SeeBlue Plus2 Prestained Standard (ThermoFisher Scientific) for
electrophoretic separation on NuPAGE 4–12% Bis-Tris gels using the Novex Mini Cell system
(ThermoFisher Scientific). Protein transfer was performed to nitrocellulose membranes using
the iBlot system (ThermoFisher Scientific) and membranes were probed with anti-RUNX
(EPR3099, Abcam) and anti-beta-actin (AC-15, Sigma-Aldrich) primary antibodies, followed
by Horseradish Peroxidase (HRP)-conjugated goat anti-rabbit and goat anti-mouse (Thermo-
Fisher Scientific) secondary antibodies respectively, in the iBind Western System (Thermo-
Fisher Scientific). HRP activity was detected using Amersham ECL Prime Western Blotting
Detection Reagent, imaged using the BioRad ChemiDoc Touch Imaging System and analyzed
with BioRad Image Lab Software Version 6.
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Gene expression by quantitative PCR
RNA was extracted using the RNeasy Plus Micro Kit (QIAGEN) and complementary DNA was
synthesized using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific).
Quantitative PCR (qPCR) was performed using Universal ProbeLibrary assays (Roche); primers
and probes are listed in S4 Table. Expression values were normalized to beta-actin (Actb).
Single cell RNA sequencing
E14.5 P1-GFP::P2-hCD4/+ fetal livers were prepared for flow sorting as described above. Single
P2-hCD4-/+ MEPs and CMPs were sorted into 384-well plates containing lysis buffer and snap
frozen. Libraries were prepared using a modified version of the Smart-Seq2 protocol [89].
Briefly, cDNA was prepared using a Mantis platform (Formulatrix) and quantified with quan-
tIT picogreen reagent (Thermo Fisher). Dual indexed sequencing libraries were prepared from
0.1ng cDNA using an Echo525 automation system (Labcyte) in miniaturized reaction vol-
umes. The library pool was quantified by qPCR using a Library Quantification Kit for Illumina
sequencing platforms (Kapa Biosystems). Paired-end 75bp sequencing was carried out by clus-
tering 1.5pM of the library pool on a NextSeq 500 sequencer (Illumina).
Base call files generated from the NextSeq 500 sequencing run were converted to the
FASTQ format with the bcl2fast converter (Illumina). All FASTQ files corresponding to the
same sample (derived from separately sequenced lanes) were then merged into a single
FASTQ file (one per sample). Read trimming was performed with trimmomatic (v0.36) with
the following settings “CROP:75 HEADCROP:5 SLIDINGWINDOW:20:20 MINLEN:36”.
The mouse reference genome GRCm38 (version M12, Ensembl release 87) and the ERCC ref-
erence sequence (Thermo Fisher) were combined and used as the reference genome for
sequencing alignment, performed using STAR (version 2.4.2a) [90]. The expression levels of
49,585 features annotated in the GENCODE mouse genome and 92 ERCC features were deter-
mined using HTSeq (version 0.6.1p1) [91]. The following parameters were specified for the
HTSeq quantification: ‘—format = bam–stranded = no–type = exon’.
Single cell count data were loaded into the R environment (R version 3.4.0) as a SCESet
object using the Scater package (version 1.4.0) [92]. Normalized gene expression values were
taken from the default normalization performed by scater. Cells with fewer than 250,000
sequencing reads, more than 25% unmapped reads, and more than 15% ERCC content were
removed. Low abundance genes (mean count<1) were excluded, as were overrepresented
genes (>20% of total sequencing reads). Differentially expressed genes were identified using
DESeq2 (version 1.16.1, Bioconductor). Prior to differential expression analysis, the data were
filtered to remove genes with a dropout rate of higher than 75%; differential expression analy-
sis was then performed using the function “DESeqDataSetFromMatrix” and by specifying the
contrast of interest. The full scripts for the analysis of these data are available at https://github.
com/m-zaki/CRUKMI_github/tree/master/JuliaDraper_PLOSgenetics.
The data discussed in this publication have been deposited in the NCBI Gene Expression
Omnibus [93,94] and are accessible through GEO series accession number GSE107653.
Statistical analysis
For FACS purified populations (MEPs, CMPs) a sample size of n = 1 refers to tissues pooled
from embryos from one litter. For total fetal liver analyses (Western blot, total FL culture), a
sample size of n = 1 refers to one embryo.
Data were evaluated using an Ordinary 2-way ANOVA and expressed as mean ± standard
error of the mean (SEM). P<0.05 was considered statistically significant.
P<0.05, P<0.01, P<0.001, P<0.0001
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Supporting information
S1 Fig. Lineage output of Lin- Sca1high cKithigh (LSK), GMP and MkP Hematopoietic Stem
and Progenitor Cells (Relating to Fig 1). A. Differential CFU-C activity of E14.5 fetal liver
cKit- cells, GMPs and MkPs. N = 3.
B-F. Flow cytometric analysis of wild type (WT) E14.5 fetal liver GMPs and MkPs. B. Repre-
sentative FACS plot of CD55/CD150 expression in GMPs. C. Quantitation of CD55low
CD150low and CD55mid/high GMPs. D-E. Representative FACS plots of total immunophenoty-
pic MkP fraction (D) and CD55/CD150 expression in MkPs (E). F. Quantitation of CD55-
CD150-, CD55+ CD150- and CD55+ CD150+ MkPs. N = 3.
G-H. Extended characterization of OP9 co-cultured CD55- CD150- MEPs. G. Representative
FACS plots of CD11b/GR1 and C-KIT expression of day 7 cultures. H. Quantitation of
CD11b+ GR1+ GM and C-KIT+ populations. N = 3.
I. Representative FACS plots of E14.5 fetal liver LSK populations.
J. Differential CFU-C activity of E14.5 fetal liver LSK CD150+ CD48- Hematopoietic Stem
Cells (HSCs), LSK CD150- CD48- MPPs (CD48- MPPs), LSK CD48+ CD150+ MPPs and LSK
CD48+ CD150- MPPs. N = 3.
K-L. Short-term (20 hours) differentiation of wild type LSK hematopoietic stem and progeni-
tor cells in pro-myeloid liquid culture. K. Representative FACS plots of cultured LSK hemato-
poietic stem and progenitor cells. L. Proportions of immunophenotypic LK and LSK
hematopoietic stem and progenitor cells in short-term cultures. Top: total Lin and cKit popu-
lations; Middle: Differential CD150/CD48-expressing LSK populations; Bottom: CMP, MEP,
GMP and MkP populations. N = 4.
M-N. Short-term differentiation of wild type E9.5 yolk sac cells, either directly in pro-myeloid
liquid culture or explant culture followed by pro-myeloid liquid culture. M. Representative
FACS plots of uncultured and cultured E9.5 yolk sac cells. N. Proportions of immunophenoty-
pic LK and LSK populations from yolk sac cells, with or without culture. Top: total Lin and
cKit populations; Bottom: immunophenotypic CMP, MEP, GMP, MkP and LK CD16/32-
CD150- CD41+ populations. E9.5 YS, N = 9; 24hr Pro-myeloid, N = 5; 48hr Pro-myeloid,
N = 4; Explant, N = 8.
(PDF)
S2 Fig. Lineage output of E12.5 and E13.5 Fetal Liver Runx1-P1-GFP::P2-hCD4 MEPs
(Relating to Fig 2). A-B. Differential CFU-C activity of E12.5 (A, N = 3) and E13.5 (B, N = 4)
fetal liver wild type, P2-hCD4- and P2-hCD4+ MEPs.
C-F. Lineage output of day 7 OP9 co-cultured fetal liver wild type, P2-hCD4- and P2-hCD4+
MEPs.C-D. Representative FACS plots of TER119 and CD41 expression in E12.5 (C) and
E13.5 (D) cultured MEPs. E-F. Proportion of TER119+ erythroid and CD41+ megakaryocyte
cells in E12.5 (E, N = 3) and E13.5 (F, N = 4) MEP cultures.
(PDF)
S3 Fig. Lineage output of E12.5 and E13.5 Fetal Liver Runx1 P1-GFP::P2-hCD4CMPs
(Relating to Fig 3). A-B. Differential CFU-C activity of E12.5 (A, N = 3) and E13.5 (B, N = 4)
fetal liver wild type, P2-hCD4- and P2-hCD4+ CMPs.
C-F. Lineage output of day 7 OP9 co-cultured fetal liver wild type, P2-hCD4- and P2-hCD4+
CMPs. C-D. Representative FACS plots of CD11b/GR1 and TER119/CD41 expression in
E12.5 (C) and E13.5 (D) cultured CMPs. E-F. Proportion of CD11b+ GR1+ granulocyte/mono-
cyte, TER119+ erythroid and CD41+ megakaryocyte cells in E12.5 (E, N = 3) and E13.5 (F,
N = 4) CMP cultures.
(PDF)
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S4 Fig. Characterization of CD31-/+ MEPs and CD31low/high CMPs (Relating to Fig 4).
A. Principal component analysis of the single cell RNA sequencing expression data from
CD41- CD150+ P2-hCD4- and P2-hCD4+ MEPs and CMPs (P2- MEP, P2+ MEP, P2- CMP,
P2+ CMP). Top: cells are color-coded according to the sorted population. Middle and Bottom
plots: cells are color-coded according to their expression of Klf1 (2nd row), Fli1 (3rd row) and
Spi1 (bottom row).
B. Violin plots of expression of selected cell surface marker genes in single P2- and P2+ MEPs,
determined by RNA sequencing.
C. Representative FACS plots characterizing CD31, CD45, CD48, Endoglin, CD11b, Tie2,
Flk1, CD44, CD144, CD24, CD29, CD43, CD140a and CD184 expression in Runx1 P2-hCD4-
and P2-hCD4+ E14.5 fetal liver cells.
D. Numbers of DAPI+, CD31+, P1-GFP+ and P2-RFP+ cells in E14.5 P1-GFP::P2-RFP FL sec-
tions. N = 3 independent samples.
E. CD48/CD45 expression in wild type E14.5 CD41- CD150+ MEPs and CMPs.
F. CD31/GFI1b-GFP expression in Gfi1b-GFP/+E14.5 CD41- CD150+ MEPs and CMPs.
G. CD31/GFI1-GFP expression in Gfi1-GFP/+E14.5 CD41- CD150+ MEPs and CMPs.
H-I. Lineage output of single cultured wild type CD31- and CD31+ MEPs in MethoCult semi-
solid myeloid culture medium (H) and OP9 co-cultures (I).
J. Lineage output of single cultured wild type CD31low and CD31high CMPs in OP9 co-cultures.
K-N. Short-term (14 hours) differentiation of wild type CD31-/+ MEPs and CD31low/high CMPs in
pro-myeloid liquid culture. K-L. Representative FACS plots of cultured MEPs (K) and CMPs (L).
M. Proportions of immunophenotypic MkPs and MEPs in short-term MEP cultures, N = 6. N.
Proportions of immunophenotypic MkPs, MEPs, GMPs and CMPs in short-term CMP cultures,
N = 4.
(PDF)
S5 Fig. Characterization of E16.5 Fetal Liver CMPs and MEPs (Relating to Fig 4). A-B.
Expression of Runx1-P1-GFP and P2-hCD4 in P1-GFP::P2-hCD4/+E16.5 fetal liver CD41-
CD150+ MEPs and CMPs. A. Representative FACS plots. B. Quantitation of the proportions of
P1- P2-, P1+ P2-, P1+ P2+ and P1- P2+ MEPs and CMPs as a percentage of total live red blood
cell lysed E16.5 fetal liver cells. N = 3.
C-D. Differential CFU-C activity of P2-hCD4- and P2-hCD4+ E16.5 fetal liver CD41- CD150+
MEPs (C) and CMPs (D). N = 5.
E-H. Lineage output of day 7 OP9 co-cultured P2-hCD4- and P2-hCD4+ CD41- CD150+ MEPs
and CMPs. E-F. Representative FACS plots of TER119/CD41 and CD11b/GR1. G-H. Propor-
tions of granulocyte/monocyte, erythroid and megakaryocyte cells. N = 5.
I. Representative FACS plots of CD31 expression in P1-GFP::P2-hCD4/+E16.5 FL P2-hCD4-
and P2-hCD4+ LK cells.
J. Representative FACS plots of CD31/CD45 expression in wild type E16.5 fetal liver CD41-
CD150+ MEPs and CMPs.
K-L. Differential CFU-C activity in wild type E16.5 fetal liver CD31-/+ MEPs (K) and
CD31low/high CMPs (L). N = 5.
M-P. Lineage output of OP9 co-cultured MEPs and CMPs. M. Representative FACS plots of
TER119 and CD41 expression of day 7 OP9 co-cultured wild type E16.5 MEPs. N. Representa-
tive FACS plots of CD11b, GR1, TER119 and CD41 expression of day 7 OP9 co-cultured wild
type E16.5 CMPs. O. Proportion of TER119+ erythroid cells and CD41+ megakaryocyte cells in
day 7 OP9 wild type E16.5 MEP co-cultures. P. Proportions of granulocytes/monocytes, ery-
throid cells and megakaryocytes in day 7 OP9 wild type E16.5 CMPs co-cultures. N = 5.
(PDF)
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S6 Fig. Impaired Mk/Ery Maturation in Runx1-null Fetal Liver (Relating to Fig 5).
A. RUNX1/ACTINB Western blot of total protein extract from wild type, Runx1-del/+ and
Runx1-del/del E14.5 fetal liver. Representative of 3 independent experiments.
B-E. Characterization of erythroid lineage subsets S0-S5 in wild type, Runx1-del/+ and Runx1-
del/del E14.5 fetal liver. B. Representative FACS plots of CD71/TER119 expression. C-E. Quan-
titation of S0 (CD71-/low TER119-), S1 (CD71high TER119-), S2 (CD71high TER119low) (C), S3
(CD71high TER119high) (D), S4 (CD71low TER119high) and S5 (CD71- TER119high) (E) ery-
throid populations. WT N = 10, Runx1-del/+ N = 9, Runx1-del/del N = 3.
F-G. Characterization of CD41high CD42d- and CD41high CD42d+ megakaryocytes from day 7
total fetal liver cultures (wild type, Runx1-del/+ and Runx1-del/del). F. Representative FACS
plots of CD41/CD42d expression. G. Quantitation of megakaryocytic CD41high CD42d- and
mature megakaryocyte CD41high CD42d+ fractions. WT N = 10, Runx1-del/+ N = 9, Runx1-
del/del N = 3.
H. Morphologic analysis of day 7 cultured megakaryocytes, stained with May-Gru¨nwald
Giemsa reagent.
(PDF)
S7 Fig. Characterization of Runx1-null progenitors (Relating to Fig 5). A-B. Characteriza-
tion of myeloid progenitor populations in wild type, Runx1-del/+ and Runx1-del/del E14.5 FL.
A. Representative FACS plots of MEP, CMP, GMP and MkP populations. B. Quantitation of
myeloid hematopoietic progenitors. N = 6.
C-F. Differential CFU-C activity of CD31- MEPs (C), CD31+ MEPs (D), CD31low CMPs (E)
and CD31high CMPs (F). N = 5.
G-I. Lineage output of bulk OP9 co-cultured wild type, Runx1-del/+ and Runx1-del/del E14.5
fetal liver CD31- and CD31+ MEPs. G. Representative FACS plots of TER119/CD41 expres-
sion. H-I. Quantitation of TER119+ erythroid and CD41+ megakaryocyte cells in CD31- MEP
(H) and CD31+ MEP (I) co-cultures. N = 4.
J-K. Lineage output of bulk OP9 co-cultured wild type, Runx1-del/+ and Runx1-del/del E14.5
fetal liver CD31high CMPs. J. Representative FACS plots of CD11b/GR1 and TER119/CD41
expression. K. Quantitation of CD11b+ GR1+ granulocyte/monocyte, TER119+ erythroid and
CD41+ megakaryocyte cells in CD31high CMP co-cultures. N = 4.
L-P. Lineage output of single OP9 co-cultured wild type, Runx1-del/+ and Runx1-del/del E14.5
fetal liver CMPs. L. Quantitation of CD11b+ GR1+ granulocyte/monocyte, TER119+ erythroid
and CD41+ megakaryocyte populations in CD31low CMPs. M. Ternary plots displaying pro-
portions of granulocyte/monocyte, erythroid and megakaryocyte cells in each positive well for
CD31high CMPs. N. Quantitation of CD11b+ GR1+ granulocyte/monocyte, TER119+ erythroid
and CD41+ megakaryocyte populations in CD31high CMP cultures. O. Proportions of uniline-
age (Ery, Mk and GM only) and multilineage (Mk + Ery, Mk + GM, Ery + GM and GEMM)
wells derived from CD31high CMPs. P. TER119 Median Fluorescence Intensity of cells of
TER119+ cells. N = 3.
Q-R. Quantitative PCR analysis of the expression of selected RUNX1-target and/or hemato-
poietic lineage-associated genes in CD31low and CD31high CMPs. Q. Expression of RUNX1-as-
sociated transcription factors. R. Expression of other megakaryocytic and erythroid markers.
N = 3
(PDF)
S8 Fig. Mk/Ery maturation in Runx1-P1-MRIPVFetal Liver (Relating to Fig 6). A. RUNX1/
ACTINB Western blot of total protein extract from wild type, Runx1-P1-MRIPV/+ and
Runx1-P1-MRIPV/MRIPVE14.5 fetal liver. Representative of 3 independent experiments.
B-E. Characterization of erythroid lineage subsets S0-S5 in wild type, Runx1-P1-MRIPV/+ and
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Runx1-MRIPV/MRIPV E14.5 fetal liver. B. Representative FACS plots of CD71/TER119
expression. C-E. Quantitation of S0, S1 and S2 (C), S3 (D), and S4 and S5 (E) erythroid popula-
tions. WT N = 12, Runx1-P1-MRIPV/+ N = 9, Runx1-P1-MRIPV/MRIPV N = 9.
F-G. Characterization of CD41high CD42d- and CD41high CD42d+ megakaryocytes from day 7
total fetal liver cultures (Runx1 wild type, P1-MRIPV/+ and P1-MRIPV/MRIPV). F. Represen-
tative FACS plots of CD41/CD42d expression. G. Quantitation of megakaryocyte CD41high
CD42d- and mature megakaryocyte CD41high CD42d+ fractions. WT N = 12, Runx1-P1-M-
RIPV/+ N = 9, Runx1-P1-MRIPV/MRIPV N = 9.
(PDF)
S9 Fig. Characterization of Runx1-P1-MRIPVFetal Liver progenitors (Relating to Fig 6).
A-B. Characterization of myeloid progenitor populations in wild type, Runx1-P1-MRIPV/+
and Runx1-P1-MRIPV/MRIPV E14.5 fetal liver. A. Representative FACS plots of MEP, CMP,
GMP and MkP populations. B. Quantitation of myeloid hematopoietic progenitors. N = 7.
C-F. Differential CFU-C activity of CD31- MEPs (C), CD31+ MEPs (D), CD31low CMPs (E)
and CD31high CMPs (F). N = 5.
G-I. Lineage output of bulk OP9 co-cultured wild type, Runx1-P1-MRIPV/+ and Runx1-P1-M-
RIPV/MRIPV E14.5 fetal liver CD31- and CD31+ MEPs. G. Representative FACS plots of
TER119/CD41 expression. H-I. Quantitation of TER119+ erythroid and CD41+ megakaryo-
cyte cells in CD31- MEP (H) and CD31+ MEP (I) co-cultures. N = 5.
J-M. Short-term (14 hours) differentiation of E14.5 wild type, Runx1-P1-MRIPV/+ and
Runx1-P1-MRIPV/MRIPVCD31-/+ MEPs and CD31low/high CMPs in pro-myeloid liquid cul-
ture. J-K. Representative FACS plots of cultured CD31low CMPs (J) and CD31high CMPs (K).
L-M. Proportions of immunophenotypic MkPs (L) and GMPs (M) in hematopoietic progeni-
tor cultures. N = 3.
(PDF)
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